Stocktoria
Ingevity Corp NGVT
Ingevity Corp (NGVT) earns a Piotroski F-score of 6/9 (mixed financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $1.2B at a -14.3% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-02-27 | Wells Fargo | Equal-Weight (main) |
| 2026-01-29 | Wells Fargo | Equal-Weight (main) |
| 2025-12-19 | Wells Fargo | Equal-Weight (main) |
| 2025-12-10 | BMO Capital | Outperform (main) |
| 2025-11-12 | Wells Fargo | Equal-Weight (main) |
| 2025-09-05 | BMO Capital | Outperform (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 6/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.068 |
| Retained earnings / assets | 0.245 |
| EBIT / assets | 0.254 |
| Equity / liabilities | 0.018 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| NGVT | Ingevity Corp | 6/9 | 2.97 | — | -2.7% |
| BCPC | BALCHEM CORP | 8/9 | 6.82 | 35.5 | +8.8% |
| IOSP | INNOSPEC INC. | 3/9 | 7.54 | — | -3.7% |
| ACNT | ASCENT INDUSTRIES CO. | 6/9 | 8.71 | 144.9 | -7.2% |
| BLGO | BIOLARGO, INC. | — | — | — | -56.3% |
| GURE | GULF RESOURCES, INC. | 3/9 | — | — | -74.5% |
| LQMT | LIQUIDMETAL TECHNOLOGIES INC | 2/9 | -15.56 | — | — |
About Ingevity Corp
Ingevity Corporation manufactures and sells activated carbon products, derivative specialty chemicals, and engineered polymers in North America, the Asia Pacific, Europe, the Middle East, Africa, and South America. It operates through three segments: Performance Materials, Performance Chemicals, and Advanced Polymer Technologies. The Performance Materials segment engineers, manufactures, and sells hardwood-based and chemically activated carbon products for use in gasoline vapor emission control systems in cars, trucks, motorcycles, and boats. This segment also produces other activated carbon products for food, water, beverage, and chemical purification applications. The Performance Chemicals segment consists of road technologies and industrial specialties. This segment's products are used in pavement construction, pavement preservation, pavement reconstruction and recycling, road markings, agrochemical dispersants, lubricants, certain adhesives, rubber, and other industrial uses. The Advanced Polymer Technologies segment produces caprolactone and caprolactone-based specialty polymers for use in coatings, resins, elastomers, adhesives, bioplastics, and medical devices. It serves automotive parts manufacturers through sales representatives, third-party sales representatives, and distributors. The company was formerly known as WestRock Company, Specialty Chemicals Business and changed its name to Ingevity Corporation in September 2015. Ingevity Corporation was founded in 1964 and is headquartered in North Charleston, South Carolina.
FAQ
Is NGVT financially healthy?
Ingevity Corp's Piotroski F-score is 6/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does NGVT pay a dividend?
No, Ingevity Corp does not currently pay a dividend.
How profitable is NGVT?
In FY2025, Ingevity Corp had a net margin of -14.3% and a return on equity of -562.6%.
Is NGVT overvalued or undervalued?
Ingevity Corp trades at about 13.9× trailing earnings — below its 10-year norm (10-year range 15.0×–67.0×, median 22.3×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for NGVT?
The average Wall-Street price target for Ingevity Corp is $85.50, about 12.2% above the recent price, from 4 analysts (consensus: buy).
Is NGVT a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Ingevity Corp: a Piotroski F-score of 6/9, an Altman Z″ in the safe zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.